Developing First-in-Class Enzyme Therapeutic Candidates

We have developed a pipeline of first-in-class, oral, non-absorbed enzyme therapeutic candidates to treat patients with rare and severe metabolic disorders that affect the kidney. Our lead product candidate, reloxaliase (formerly ALLN-177), is an oral enzyme therapeutic that we are initially developing for the treatment of enteric hyperoxaluria in adults. Our second product candidate, ALLN-346, is being developed for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders.

Scroll to Top